BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

PriCara™ Release: U.S. Federal Circuit Court of Appeals Rules Patent for ACIPHEX(R) Valid and Enforceable


7/22/2008 7:23:39 AM

RARITAN, N.J., July 21, 2008 /PRNewswire/ -- PriCara,(TM) Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., announced today that the U.S. Federal Circuit Court of Appeals affirmed the judgments of the United States District Court for the Southern District of New York that the patent for ACIPHEX(R) (rabeprazole sodium 20 mg tablets) is valid and enforceable.

Today's decision ensures that the patent for ACIPHEX remains in force and also directs the U.S. Food and Drug Administration to change the effective date of Teva Pharmaceutical's approval to market its generic version of rabeprazole sodium to no earlier than May 2013, the date of the ACIPHEX patent expiration. The court's decision also affects Dr. Reddy's pharmaceutical company's application for approval for its generic version of the drug, which now will not receive final approval before May 2013.

Eisai Co., Ltd. of Tokyo, Japan, holds the patent for ACIPHEX. PriCara and Eisai Inc. co-promote ACIPHEX in the United States.

"We are pleased by the court's decision, which reflects our belief that the patent for ACIPHEX is both valid and enforceable," said Jim Mitchell, General Manager, PriCara.

ACIPHEX is used for the treatment of persistent heartburn and other symptoms associated with acid reflux disease. It also is used for the short- term treatment in the healing and symptom relief of erosive acid reflux disease -- gastroesophageal reflux disease -- and to maintain healing of erosion and relief of heartburn symptoms that happen with acid reflux disease.

ACIPHEX has a well-established safety profile. The most common side effect possibly related to ACIPHEX is headache. Symptom relief does not rule out other serious stomach conditions. Patients on warfarin (such as Coumadin(R)) may need to be monitored closely by their doctor. For more information, visit www.aciphex.com.

About PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

PriCara(TM), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., is a major healthcare organization in the United States dedicated to the needs of primary care providers who serve a vital role on the frontlines of medicine. For more information about the company, please visit www.PriCara.com.

Ortho-McNeil-Janssen Pharmaceuticals, Inc. is a wholly owned subsidiary of Johnson & Johnson.

[This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from PriCara's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. PriCara does not undertake to update any forward-looking statements as a result of new information or future events or developments.]

CONTACT: Media: Greg Panico, +1-908-927-3715, Gpanico1@gpcus.jnj.com,
PriCara(TM), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.;
Investors: Louise Mehrotra, +1-732-524-6491, or Lesley Fishman, +1-732-524-
3922, Johnson & Johnson

Web site: http://www.PriCara.com/
http://www.jnj.com/
http://www.aciphex.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES